ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) - Panel: Emerging Therapies for Psychiatric Disorders Transcript

Sep 09, 2020 / 05:30PM GMT
Release Date Price: $37.9 (-0.79%)
Neena Marie Bitritto;Garg
Citigroup Inc. Exchange Research - Research Analyst

I think we're live, right, now?

Joel Lawrence Beatty
Citigroup Inc., Research Division - VP & Analyst

Yes.

Neena Marie Bitritto;Garg
Citigroup Inc. Exchange Research - Research Analyst

Okay. Oh hi, everyone. Thank you so much for joining the Citi 15th Annual Biopharma Conference. My name is Neena Bitritto-Garg. I am one of the smid-cap biotech analysts here at Citi. So I am very pleased to have with us today management teams from ACADIA. So we have Serge from ACADIA. We have also management teams from Minerva Neurosciences and from Karuna as well. And I'm also joined by my colleagues, Joel Beatty and Mohit, if they want to give some introductory remarks to introduce their management teams as well.

Mohit Bansal
Citigroup Inc., Research Division - Director and Analyst

Great. I mean, from my side, I mean, we have Steve Paul, the CEO of Karuna with us, and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot